Literature DB >> 30401981

TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.

Akihiro Matsushita1,2, Tatsuhiro Sato1, Satomi Mukai1, Teruaki Fujishita3, Emi Mishiro-Sato3, Maho Okuda1, Masahiro Aoki3,4, Yoshinori Hasegawa2, Yoshitaka Sekido5,6.   

Abstract

Malignant mesothelioma (MM) constitutes a very aggressive tumor that is caused by asbestos exposure after long latency. The NF2 tumor suppressor gene is mutated in 40-50% of MM; moreover, one of its downstream signaling cascades, the Hippo signaling pathway, is also frequently inactivated in MM cells. Although the YAP transcriptional coactivator, which is regulated by the Hippo pathway, can function as a pro-oncogenic protein, the role of TAZ, a paralog of YAP, in MM cells has not yet been clarified. Here, we show that TAZ is expressed and underphosphorylated (activated) in the majority of MM cells compared to immortalized mesothelial cells. ShRNA-mediated TAZ knockdown highly suppressed cell proliferation, anchorage-independent growth, cell motility, and invasion in MM cells harboring activated TAZ. Conversely, transduction of an activated form of TAZ in immortalized mesothelial cells enhanced these in vitro phenotypes and conferred tumorigenicity in vivo. Microarray analysis determined that activated TAZ most significantly enhanced the transcription of genes related to "cytokine-cytokine receptor interaction." Among selected cytokines, we found that IL-1 signaling activation plays a major role in proliferation in TAZ-activated MM cells. Both IL1B knockdown and an IL-1 receptor antagonist significantly suppressed malignant phenotypes of immortalized mesothelial cells and MM cells with activated TAZ. Overall, these results indicate an oncogenic role for TAZ in MMs via transcriptional induction of distinct pro-oncogenic genes including cytokines. Among these, IL-1 signaling appears as one of the most important cascades, thus potentially serving as a target pathway in MM cells harboring Hippo pathway inactivation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30401981     DOI: 10.1038/s41388-018-0417-7

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.

Authors:  T Mizuno; H Murakami; M Fujii; F Ishiguro; I Tanaka; Y Kondo; S Akatsuka; S Toyokuni; K Yokoi; H Osada; Y Sekido
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

Review 2.  Advances in malignant mesothelioma.

Authors:  Bruce W S Robinson; Richard A Lake
Journal:  N Engl J Med       Date:  2005-10-13       Impact factor: 91.245

Review 3.  Optimal Therapy of Advanced Stage Mesothelioma.

Authors:  Maria M J Disselhorst; Sjaak J A Burgers; Paul Baas
Journal:  Curr Treat Options Oncol       Date:  2017-08

4.  Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas.

Authors:  Yasuo Adachi; Chieko Aoki; Naoko Yoshio-Hoshino; Koichi Takayama; David T Curiel; Norihiro Nishimoto
Journal:  Int J Cancer       Date:  2006-09-15       Impact factor: 7.396

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 6.  The emerging roles of YAP and TAZ in cancer.

Authors:  Toshiro Moroishi; Carsten Gram Hansen; Kun-Liang Guan
Journal:  Nat Rev Cancer       Date:  2015-01-16       Impact factor: 60.716

Review 7.  Novel insights into mesothelioma biology and implications for therapy.

Authors:  Timothy A Yap; Joachim G Aerts; Sanjay Popat; Dean A Fennell
Journal:  Nat Rev Cancer       Date:  2017-07-25       Impact factor: 60.716

8.  LATS2 is a tumor suppressor gene of malignant mesothelioma.

Authors:  Hideki Murakami; Tetsuya Mizuno; Tetsuo Taniguchi; Makiko Fujii; Futoshi Ishiguro; Takayuki Fukui; Shinya Akatsuka; Yoshitsugu Horio; Toyoaki Hida; Yutaka Kondo; Shinya Toyokuni; Hirotaka Osada; Yoshitaka Sekido
Journal:  Cancer Res       Date:  2011-01-18       Impact factor: 12.701

Review 9.  YAP/TAZ at the Roots of Cancer.

Authors:  Francesca Zanconato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Cancer Cell       Date:  2016-06-13       Impact factor: 31.743

10.  TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth.

Authors:  Makiko Fujii; Takeshi Toyoda; Hayao Nakanishi; Yasushi Yatabe; Ayuko Sato; Yasue Matsudaira; Hidemi Ito; Hideki Murakami; Yutaka Kondo; Eisaku Kondo; Toyoaki Hida; Tohru Tsujimura; Hirotaka Osada; Yoshitaka Sekido
Journal:  J Exp Med       Date:  2012-02-13       Impact factor: 14.307

View more
  7 in total

1.  The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.

Authors:  Sivaveera Kandasamy; Gautam Adhikary; Ellen A Rorke; Joseph S Friedberg; McKayla B Mickle; H Richard Alexander; Richard L Eckert
Journal:  Mol Cancer Res       Date:  2019-11-15       Impact factor: 5.852

2.  The Hippo Pathway Effector Transcriptional Co-activator With PDZ-Binding Motif Correlates With Clinical Prognosis and Immune Infiltration in Colorectal Cancer.

Authors:  Yutong Wang; Hui Nie; Huiling Li; Zhiming Liao; Xuejie Yang; Xiaoyun He; Jian Ma; Jianhua Zhou; Chunlin Ou
Journal:  Front Med (Lausanne)       Date:  2022-07-05

3.  YAP1 is essential for malignant mesothelioma tumor maintenance.

Authors:  Loreley Calvet; Odette Dos-Santos; Emmanuel Spanakis; Véronique Jean-Baptiste; Jean-Christophe Le Bail; Armelle Buzy; Pascal Paul; Christophe Henry; Sandrine Valence; Colette Dib; Jack Pollard; Sukhvinder Sidhu; Jürgen Moll; Laurent Debussche; Iris Valtingojer
Journal:  BMC Cancer       Date:  2022-06-10       Impact factor: 4.638

4.  Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.

Authors:  Anna-Mariya Kukuyan; Eleonora Sementino; Yuwaraj Kadariya; Craig W Menges; Mitchell Cheung; Yinfei Tan; Kathy Q Cai; Michael J Slifker; Suraj Peri; Andres J Klein-Szanto; Frank J Rauscher; Joseph R Testa
Journal:  Cancer Res       Date:  2019-05-31       Impact factor: 13.312

Review 5.  A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations.

Authors:  Hirohito Yamaguchi; Ghina M Taouk
Journal:  Front Oncol       Date:  2020-06-11       Impact factor: 6.244

6.  YAP and TAZ in Lung Development: The Timing Is Important.

Authors:  David Warburton
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

7.  Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches-a narrative review.

Authors:  Alicia A Zolondick; Giovanni Gaudino; Jiaming Xue; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Precis Cancer Med       Date:  2021-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.